Association between factor VII polymorphisms and blood pressure: The stanislas cohort

Hypertension

Volumn 44, Issue 5, 2004, Pages 674-680

  Sass, Catherine ^a   Blanquart, Christine ^b   Morange, Pierre Emmanuel ^c   Pfister, Michèle ^a   Visvikis Siest, Sophie ^a  

^a INSERM   (France)

^b Fournier Laboratories   (France)

^c TIMONE HOSPITAL   (France)

Author keywords

Blood pressure; Genetics; Hypertension; Rheology; Thrombin

Indexed keywords

BLOOD CLOTTING FACTOR 7;

ADULT; ALLELE; ARTICLE; BLOOD PRESSURE; BLOOD SAMPLING; CARDIOVASCULAR RISK; CLINICAL TRIAL; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; COVARIANCE; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; FEMALE; FRANCE; GENE LOCUS; GENE MUTATION; GENETIC POLYMORPHISM; HUMAN; HYPERTENSION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PAENIBACILLUS; PATIENT SELECTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE;

ADULT; BLOOD PRESSURE; CHILD; COHORT STUDIES; FACTOR VII; FEMALE; GENOTYPE; HUMANS; HYPERTENSION; LONGITUDINAL STUDIES; MALE; POLYMORPHISM, GENETIC;

EID: 7244223221     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000144799.41945.a5     Document Type: Article

References (46)

1. Andrioli G, Ortolani R, Fontana L, Gaino S, Bellavite P, Lechi C, Minuz P, Manzato F, Trideme G, Lechi A. Study of platelet adhesion in patients with uncomplicated hypertension. J Hypertens. 1996;14:1215-1221.
2. de Simone G, Devereux RB, Chien S, Alderman MH, Atlas SA, Laragh JH. Relation of blood viscosity to demographic and physiologic variables and to cardiovascular risk factors in apparently normal adults. Circulation. 1990;81:107-117.
3. Folsom AR, Peacock JM, Nieto FJ, Rosamond WD, Eigenbrodt ML, Davis CE, Wu KK. Plasma fibrinogen and incident hypertension in the Atherosclerosis Risk in Communities (ARIC) Study. J Hypertens. 1998; 16:1579-1583.
4. Lee AJ. Haemorheological, platelet and endothelial factors in essential hypertension. J Hum Hypertens. 2002;16:529-531.
5. Moser M, Patterson C. Thrombin and vascular development: a sticky subject. Arterioscler Thromb Vasc Biol. 2003;23:922-930.
6. Coughlin SR. How thrombin 'talks' to cells: molecular mechanisms and roles in vivo. Arterioscler Thromb Vasc Biol. 1998;18:514-518.
7. Sicker T, Wuchold F, Kaiser B, Glusa E. Systemic vascular effects of thrombin and thrombin receptor activating peptide in rats. Thromb Res. 2001;101:467-475.
8. Major CD, Santulli RJ, Derian CK, Andrade-Gordon P. Extracellular mediators in atherosclerosis and thrombosis: lessons from thrombin receptor knockout mice. Arterioscler Thromb Vasc Biol. 2003;23: 931-939.
9. Hembrough TA, Swartz GM, Papathanassiu A, Vlasuk GP, Rote WE, Green SJ, Pribluda VS. Tissue factor/factor Vila inhibitors block angiogenesis and tumor growth through a nonhemostatic mechanism. Cancer Res. 2003;63:2997-3000.
10. Camerer E, Rottingen JA, Gjeraes E, Larsen K, Skartlien AH, Iversen JG, Prydz H. Coagulation factors VIIa and Xa induce cell signaling leading to up-regulation of the egr-1 gene. J Biol Chem. 1999;274:32225-32233.
11. Ollivier V, Bentolila S, Chabbat J, Hakim J, de Prost D. Tissue factor-dependent vascular endothelial growth factor production by human fibroblasts in response to activated factor VII. Blood. 1998;91:2698-2703.
12. Porreca E, Di Febbo C, Di Castelnuovo A, Baccante G, Amore C, Angelini A, Di Nisio M, Donati MB, Cuccurullo F, Iacoviello L. Association of factor VII levels with inflammatory parameters in hypercholesterolemic patients. Atherosclerosis. 2002;165:159-166.
13. De Jonge E, Friederich PW, Vlasuk GP, Rote WE, Vroom MB, Levi M, Van Der PT. Activation of coagulation by administration of recombinant factor Vila elicits interleukin (IL) 6 and IL-8 release in healthy human subjects. Clin Diagn Lab Immunol. 2003;10:495-497.
14. Cushman M, Yanez D, Psaty BM, Fried LP, Heiss G, Lee M, Polak JF, Savage PJ, Tracy RP. Association of fibrinogen and coagulation factors VII and VIII with cardiovascular risk factors in the elderly: the Cardiovascular Health Study. Cardiovascular Health Study Investigators. Am J Epidemiol. 1996;143:665-676.
15. Woodward M, Lowe GD, Rumley A, Tunstall-Pedoe H, Philippou H, Lane DA, Morrison CE. Epidemiology of coagulation factors, inhibitors and activation markers: the third Glasgow MONICA survey, II: relationships to cardiovascular risk factors and prevalent cardiovascular disease. Br J Haematol. 1997;97:785-797.
16. Kario K, Matsuo T, Kobayashi H, Matsuo M, Sakata T, Miyata T, Shimada K. Factor VII hyperactivity and endothelial cell damage are found in elderly hypertensives only when concomitant with microalbuminuria. Arterioscler Thromb Vasc Biol. 1996;16:455-461.
17. Green F, Kelleher C, Wilkes H, Temple A, Meade T, Humphries S. A common genetic polymorphism associated with lower coagulation factor VII levels in healthy individuals. Arterioscler Thromb. 1991;11:540-546.
18. Marchetti G, Patracchini P, Gemmati D, DeRosa V, Pinotti M, Rodorigo G, Casonato A, Girolami A, Bernardi F. Detection of two missense mutations and characterization of a repeat polymorphism in the factor VII gene (F7). Hum Genet. 1992;89:497-502.
19. Hunault M, Arbini AA, Lopaciuk S, Carew JA, Bauer KA. The Arg353Gln polymorphism reduces the level of coagulation factor VII: in vivo and in vitro studies. Arterioscler Thromb Vasc Biol. 1997;17: 2825-2829.
20. Ghaddar HM, Folsom AR, Aleksic N, Hearne LB, Chambless LE, Morrissey JH, Wu KK. Correlation of factor VIIa values with factor VII gene polymorphism, fasting and postprandial triglyceride levels, and subclinical carotid atherosclerosis. Circulation. 1998;98:2815-2821.
21. Hegele RA, Brunt JH, Connelly PW. Genetic and biochemical factors associated with variation in blood pressure in a genetic isolate. Hypertension. 1996;27:308-312.
22. Siest G, Visvikis S, Herbeth B, Gueguen R, Vincent-Viry M, Sass C, Beaud B, Lecomte E, Steinmetz J, Locuty J, Chevrier P. Objectives, design and recruitment of a familial and longitudinal cohort for studying gene-environment interactions in the field of cardiovascular risk: the Stanislas cohort. Clin Chem Lab Med. 1998;36:35-42.
23. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560-2572.
24. Cheng S, Grow MA, Pallaud C, Klitz W, Erlich HA, Visvikis S, Chen JJ, Pullinger CR, Malloy MJ, Siest G, Kane JP. A multilocus genotyping assay for candidate markers of cardiovascular disease risk. Genome Res. 1999;9:936-949.
25. Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics. 1986;42:121-130.
26. Lane A, Green F, Scarabin PY, Nicaud V, Bara L, Humphries S, Evans A, Luc G, Cambou JP, Arveiler D, Cambien F. Factor VII Arg/Gln353 polymorphism determines factor VII coagulant activity in patients with myocardial infarction (MI) and control subjects in Belfast and in France but is not a strong indicator of MI risk in the ECTIM study. Atherosclerosis. 1996;119:119-127.
27. Hennekens CH. Lessons from hypertension trials. Am J Med. 1998;104: 50S-53S.
28. Iacoviello L, Di Castelnuovo A, de Knijff P, D'Orazio A, Amore C, Arboretti R, Kluft C, Donati MB. Polymorphisms in the coagulation factor VII gene and the risk of myocardial infarction. N Engl J Med. 1998;338:79-85.
29. Girelli D, Russo C, Ferraresi P, Olivieri O, Pinotti M, Friso S, Manzato F, Mazzucco A, Bernardi F, Corrocher R. Polymorphisms in the factor VII gene and the risk of myocardial infarction in patients with coronary artery disease. N Engl J Med. 2000;343:774-780.
30. Di Castelnuovo A, D'Orazio A, Amore C, Falanga A, Donati MB, Iacoviello L. The decanucleotide insertion/deletion polymorphism in the promoter region of the coagulation factor VII gene and the risk of familial myocardial infarction. Thromb Res. 2000;98:9-17.
31. Atherosclerosis Thrombosis and Vascular Biology Italian Study Group. No evidence of association between prothrombotic gene polymorphisms and the development of acute myocardial infarction at a young age. Circulation. 2003;107:1117-1122.
32. Freeman MS, Mansfield MW, Barrett JH, Grant PJ. Genetic contribution to circulating levels of hemostatic factors in healthy families with effects of known genetic polymorphisms on heritability. Arterioscler Thromb Vasc Biol. 2002;22:506-510.
33. Bernardi F, Marchetti G, Pinotti M, Arcieri P, Baroncini C, Papacchini M, Zepponi E, Ursicino N, Chiarotti F, Mariani G. Factor VII gene polymorphisms contribute about one third of the factor VII level variation in plasma. Arch Pathol Lab Med. 1996;16:72-76.
34. Pollak ES, Hung HL, Godin W, Overton GC, High KA. Functional characterization of the human factor VII 5′-flanking region. J Biol Chem. 1996;271:1738-1747.
35. Lynn M, Jerokhimov I, Jewelewicz D, Popkin C, Johnson EW, Rashid QN, Brown M, Martinowitz U, Cohn SM. Early use of recombinant factor VIIa improves mean arterial pressure and may potentially decrease mortality in experimental hemorrhagic shock: a pilot study. J Trauma. 2002; 52:703-707.
36. Cunningham MA, Romas P, Hutchinson P, Holdsworth SR, Tipping PG. Tissue factor and factor VIIa receptor/ligand interactions induce proinflammatory effects in macrophages. Blood. 1999;94:3413-3420.
37. Lariviere R, Lebel M. Endothelin-1 in chronic renal failure and hypertension. Can J Physiol Pharmacol. 2003;81:607-621.
38. Shankar R, de la Motte CA, Poptic EJ, DiCorleto PE. Thrombin receptor-activating peptides differentially stimulate platelet-derived growth factor production, monocytic cell adhesion and E-selectin expression in human umbilical vein endothelial cells. J Biol Chem. 1994;269:13936-13941.
39. Ciuffetti G, Pasqualini L, Pirro M, Lombardini R, De Sio M, Schillaci G, Mannarino E. Blood rheology in men with essential hypertension and capillary rarefaction. J Hum Hypertens. 2002;16:533-537.
40. Chae CU, Lee RT, Rifai N, Ridker PM. Blood pressure and inflammation in apparently healthy men. Hypertension. 2001;38:399-403.
41. Dorffel Y, Latsch C, Stuhlmuller B, Schreiber S, Scholze S, Burmester GR, Scholze J. Preactivated peripheral blood monocytes in patients with essential hypertension. Hypertension. 1999;34:113-117.
42. Todorov V, Muller M, Schweda F, Kurtz A. Tumor necrosis factor-α inhibits renin gene expression. Am J Physiol Regul Integr Comp Physiol. 2002;283:R1046-R1051.
43. Fernandez-Real JM, Vayreda M, Richart C, Gutierrez C, Broch M, Vendrell J, Ricart W. Circulating IL 6 levels, blood pressure, and insulin sensitivity in apparently healthy men and women. J Clin Endocrinol Metab. 2001;86:1154-1159.
44. le Noble FA, Stassen FR, Hacking WJ, Struijker Boudier HA. Angiogenesis and hypertension. J Hypertens. 1998;16:1563-1572.
45. Antonios TF, Singer DR, Markandu ND, Mortimer PS, MacGregor GA. Rarefaction of skin capillaries in borderline essential hypertension suggests an early structural abnormality. Hypertension. 1999;34: 655-658.
46. Noon JP, Walker BR, Webb DJ, Shore AC, Holton DW, Edwards HV, Watt GC. Impaired microvascular dilatation and capillary rarefaction in young adults with a predisposition to high blood pressure. J Clin Invest. 1997;99:1873-1879.